New drug cocktail aims to stop leukemia relapse after transplant
NCT ID NCT07562568
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether adding SHR2554 and azacitidine to standard chemotherapy before a stem cell transplant can lower the chance of cancer returning in people aged 15-60 with high-risk or relapsed leukemia or myelodysplastic syndromes. Half the participants will get the new drug combo, while the other half receives standard chemo. The main goal is to see if the combo reduces relapse rates over two years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SHR2554 combined with azacitidine
What this could lead to
If successful, this combination could reduce the chance of leukemia or MDS returning after a stem cell transplant, improving long-term survival.
What could go wrong
This is an early phase 2 trial with only 160 participants, so results may not apply to everyone. The treatment involves strong chemotherapy and transplant, which carry serious risks like infection and graft-versus-host disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, 215006, China